Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients

AIDS

Volumn 23, Issue 3, 2009, Pages 426-428

  Landman, Roland ^a   Damond, Florence ^b,c   Gerbe, Juliette ^a   Brun Vezinet, Francoise ^b,c,d   Yeni, Patrick ^a,d   Matheron, Sophie ^a,d  

^a Service des Maladies Infectieuses et Tropicales   (France)

^b Laboratoire de Virologie   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; FOSAMPRENAVIR SODIUM PLUS RITONAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE; RALTEGRAVIR; RITONAVIR PLUS TIPRANAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IMMUNOLOGICAL MONITORING; MAJOR CLINICAL STUDY; MIXED INFECTION; MUTATION; PRIORITY JOURNAL; PROTEINASE INHIBITION; SERODIAGNOSIS; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD;

EID: 59849104541     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328321305a     Document Type: Article

References (18)

1. Holmgren B, da Silva Z, Larsen O, Vastrup P, Andersson S, Aaby P. Dual infections with HIV-1, HIV-2 and HTLV-I are more common in older women than in men in Guinea-Bissau. AIDS 2003; 17:241-253.
2. da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing?. AIDS 2008; 22:1195-1202.
3. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Coll-Seck AM, Curlin ME, et al. Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa. AIDS Res Hum Retroviruses 2003; 19:575-584.
4. Rayfield M, De Cock K, Heyward W, Goldstein L, Krebs J, Kwok S, et al. Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction. J Infect Dis 1988; 158:1170-1176.
5. Sagoe K, Mingle J, Affram R, Britton S, Dzokoto A, Sonnerborg A. Virological characterization of dual HIV-1/HIV-2 seropositivity and infections in Southern Ghana. Ghana Med J 2008; 42:16-21.
6. Matheron S, Pueyo S, Damond F, Simon F, Campa P, Salamon R, et al. Factors associated with clinical progression in HIV-2 infected patients: the French ANRS cohort. AIDS 2003; 17:2593-2601.
7. Sarr AD, Hamel DJ, Thior I, Kokkotou E, Marlink RG, Coll-Seck EM, et al. HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts. AIDS 1998; 12:131-137.
8. Grankvist O, Bredberg-Raden U, Gustafsson A, Albert J, Albino P, Andreasson PA, et al. Improved detection of HIV-2 DNA in clinical samples using a nested primer-based polymerase chain reaction. J Acquir Immune Defic Syndr 1992; 5:286-293.
9. Damond F, Loussert-Ajaka I, Apetrei C, Descamps D, Souquiere S, Lepretre A, et al. Highly sensitive method for amplification of human immunodeficiency virus type 2 DNA. J Clin Microbiol 1998; 36:809-811.
10. Barin F, Lahbabi Y, Buzelay L, Lejeune B, Baillou-Beaufils A, Denis F, et al. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. AIDS Res Hum Retroviruses 1996; 12:1279-1289.
11. Baillou A, Janvier B, Leonard G, Denis F, Goudeau A, Barin F. Fine serotyping of human immunodeficiency virus serotype 1 (HIV-1) and HIV-2 infections by using synthetic oligopeptides representing an immunodominant domain of HIV-1 and HIV- 2/simian immunodeficiency virus. J Clin Microbiol 1991; 29:1387-1391.
12. Barin F, Cazein F, Lot F, Pillonel J, Brunet S, Thierry D, et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS 2007; 21:2351-2353.
13. Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006; 20:1141-1150.
14. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451-458.
15. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Campa P, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545-1548.
16. Yeni P. French guidelines for the treatment of HIV-infected adults with antiretroviral therapy. Flammarion 2008:226-238.
17. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 2008; 22:1091-1092.
18. Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22:665-666.